Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07372794

EIT-Guided Respiratory Physiotherapy for Prolonged Mechanical Ventilation (PMV)

Patients with prolonged mechanical ventilation (PMV) frequently experience impaired ventilation distribution, respiratory muscle dysfunction, secretion retention, and delayed liberation from mechanical ventilation. Electrical impedance tomography (EIT) provides real-time bedside visualization of regional ventilation and enables individualized respiratory physiotherapy strategies.

This multicenter randomized controlled trial aims to evaluate whether EIT-guided respiratory physiotherapy improves ventilator-free days at day 28 compared with conventional respiratory physiotherapy in adult patients with PMV.

Respiratory physiotherapy consists of airway clearance, chest physiotherapy techniques, breathing pattern optimization, and therapeutic positioning. In the EIT-guided group, real-time EIT imaging is used to individualize physiotherapy strategies based on predefined ventilation distribution indicators, while the control group receives standardized physiotherapy according to institutional protocols without EIT guidance.

Secondary outcomes include successful liberation from mechanical ventilation, diaphragm ultrasound parameters, EIT-derived ventilation distribution indices (exploratory mechanistic outcomes), ICU Mobility Scale, healthcare resource utilization, and safety outcomes.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Beijing Rehabilitation Hospital Affiliated to Capital Medical University

Beijing, Beijing Municipality, 100144, China

Location status: Recruiting

About this study

This multicenter randomized controlled trial evaluates the effectiveness of electrical impedance tomography (EIT)-guided respiratory physiotherapy compared with conventional respiratory physiotherapy in adult patients with prolonged mechanical ventilation (PMV).

Eligible patients receiving invasive mechanical ventilation for at least 21 consecutive days will be randomly assigned in a 1:1 ratio to either the EIT-guided group or the control group, in addition to standard ICU care.

Respiratory physiotherapy consists of airway clearance, chest physiotherapy techniques, breathing pattern optimization, and therapeutic positioning. Both groups will receive standardized physiotherapy protocols with comparable treatment frequency and duration.

In the EIT-guided group, real-time EIT imaging will be used during each physiotherapy session. The control group will receive the same standardized physiotherapy components according to institutional protocols without EIT guidance.

The primary outcome is ventilator-free days at day 28 (VFD-28), defined as the number of days alive and free from invasive mechanical ventilation during the first 28 days after randomization. Patients who die before day 28 or remain invasively ventilated at day 28 will be assigned a value of zero. Reintubation within 72 hours will be considered treatment failure according to the predefined protocol.

Secondary outcomes include successful liberation from invasive mechanical ventilation by day 28, diaphragm ultrasound parameters, EIT-derived ventilation distribution indices (exploratory mechanistic outcomes), ICU Mobility Scale (IMS), healthcare resource utilization, and safety outcomes.

EIT-derived parameters are included as exploratory mechanistic outcomes to characterize physiological responses to the intervention and are not used for primary outcome adjudication.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 18 years.
  • Invasive mechanical ventilation for ≥ 21 consecutive days.
  • Clinically stable and eligible for respiratory physiotherapy as determined by the treating team.
  • Expected to remain on invasive mechanical ventilation for at least 48 hours after enrollment.
  • Written informed consent obtained from the patient or legally authorized representative.

Exclusion criteria

  • Contraindications to electrical impedance tomography .
  • Hemodynamic instability requiring high-dose vasoactive support.
  • Severe hypoxemia refractory to optimization.
  • Unstable fractures or other contraindications to mobilization or positioning.
  • Pregnancy.
  • Expected death within 48 hours.

Treatment and study plan

EIT-Guided Respiratory Physiotherapy

Other

Respiratory physiotherapy consists of airway clearance, chest physiotherapy techniques, breathing pattern optimization, and therapeutic positioning, individualized using real-time EIT guidance based on predefined ventilation distribution indicators. Link this intervention to: Experimental Arm

Conventional Respiratory Physiotherapy

Other

Respiratory physiotherapy consists of airway clearance, chest physiotherapy techniques, breathing pattern optimization, and therapeutic positioning, delivered according to standardized institutional protocols without EIT guidance. Link this intervention to: Control Arm

Primary outcomes

  1. Ventilator-Free Days at Day 28 (VFD-28)

    Time frame: 28 days

    Ventilator-free days at day 28 (VFD-28) is defined as the number of days alive and free from invasive mechanical ventilation during the first 28 days after randomization. Patients who die before day 28 or remain invasively ventilated at day 28 will be assigned a value of zero. Reintubation within 72 hours after extubation or decannulation is considered treatment failure according to the predefined protocol.

Secondary outcomes

  1. Successful liberation from invasive mechanical ventilation by day 28

    Time frame: 28 days

    Successful liberation is defined as remaining free from invasive mechanical ventilation for at least 72 consecutive hours.

  2. Diaphragm ultrasound parameters

    Time frame: Up to 28 days

    Diaphragmatic excursion, thickness, and thickening fraction measured by bedside ultrasound.

  3. EIT-derived ventilation distribution indices

    Time frame: During intervention period (up to 28 days)

    Regional ventilation distribution indices derived from electrical impedance tomography, analyzed as exploratory mechanistic outcomes and not used for primary outcome adjudication.

  4. ICU Mobility Scale (IMS) change from baseline

    Time frame: Up to ICU discharge or day 28

    Change in ICU Mobility Scale score from baseline to the highest achieved level during ICU stay.

  5. ICU length of stay

    Time frame: Up to hospital discharge

    Number of days from ICU admission to ICU discharge.

  6. Hospital length of stay

    Time frame: From hospital admission to hospital discharge

    Number of days from hospital admission to hospital discharge.

  7. Total hospitalization cost

    Time frame: Up to hospital discharge

    Total direct medical cost during hospitalization.

  8. Adverse events during physiotherapy

    Time frame: During intervention period (up to 28 days)

    Incidence of adverse events related to respiratory physiotherapy, including desaturation, hemodynamic instability, arrhythmia, or treatment intolerance.

Study contacts

Contact information is provided by the study sponsor or research team.

Sponsors and collaborators

Lead sponsor

Capital Medical University

Other

Registry information

Official study title

Electrical Impedance Tomography-Guided Respiratory Physiotherapy for Liberation From Prolonged Mechanical Ventilation: A Multicenter Randomized Controlled Trial

Acronym: PMV

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Jan 28, 2026
Registry last updated
May 4, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.